Esophageal Cancer – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 46, 45, 3, 26 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 3 and 2 molecules, respectively.
Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Esophageal Cancer – Overview
- Esophageal Cancer – Therapeutics Development
- Esophageal Cancer – Therapeutics Assessment
- Esophageal Cancer – Companies Involved in Therapeutics Development
- Esophageal Cancer – Drug Profiles
- Esophageal Cancer – Dormant Projects
- Esophageal Cancer – Discontinued Products
- Esophageal Cancer – Product Development Milestones
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rdvkt4/esophageal_cancer?w=4